Integra’s acquisition of Acclarent from Johnson & Johnson is expected to close in Q2 FY 2024. Image Credit: Michael Vi / Shutterstock.

Integra LifeSciences has entered a definitive agreement to acquire Acclarent from J&J’s MedTech company, Ethicon.

Integra will pay $275m in cash at closing, subject to customary purchase price adjustments. J&J will also be entitled to receive an additional $5m in regulatory milestone-based payments. The deal is expected to close by Q2 FY 2024. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives,” said Integra president and CEO Jan De Witte in a 13 December press release.

The number of ENT procedures in the US is forecasted to grow from 1.3 billion procedures in 2021 to approximately 1.4 billion procedures in 2030, as per a GlobalData market outlook report. The speech aid devices are expected to experience a steady growth of over 2% per year during the forecasted period.

In March, Aural Analytics’ speech vitals software received breakthrough device designation from the US Food and Drug Administration (FDA). The device was developed to help patients living with amyotrophic lateral sclerosis (ALS).

Following the acquisition, Acclarent will be part of Integra’s Codman speciality surgical (CSS) division. The CSS division generates approximately 70% of the total revenue for Integra. It generated $268.2m in revenue in Q3 FY 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects the Acclarent offering will complement its neurosurgery portfolio. CSS division president Mike McBreen said the acquisition will provide opportunities for ENT and neurosurgeons to “closely collaborate” on tumour care using skull base approaches.

The market for minimally invasive neurosurgery devices is forecasted to grow from being worth $131m in 2023 to $172m in 2030, as per a GlobalData market model. In July, Stryker launched the Q Guidance System, a cranial guidance software to help surgeons plan and carry out cranial procedures. The FDA-cleared device assists in positioning instruments and displaying patient cranial anatomy.